It was a delight to be able to discuss with Martin Metz (Charité – Universitätsmedizin Berlin, Berlin, Germany) the results of the 52-week extension study (NCT02649218), which investigated the monoclonal anti-IgE antibody, ligelizumab, in patients who had not achieved complete urticaria activity control with omalizumab.
His abstract entitled ‘Efficacy of ligelizumab in chronic spontaneous urticaria patients previously inadequately controlled with omalizumab; analysis of the Phase 2 program’ was presented at the EADV Virtual Congress, 29-31 October 2020.
- What are the limitations of the current standard of care for chronic spontaneous urticaria? (0:16)
- What is the rationale for the use of ocrelizumab in chronic spontaneous urticaria patients previously inadequately controlled with H1-antihistamines? (0:40)
- Could give us a brief overview of the 2019 Phase II study and its findings? (1:26)
- What have we learned from your recent analyses of this study’s data in terms of possible predictors of response to ligelizumab? (2:18)
- What are the implications of these findings and what further study is needed? (3:06)
Disclosures: Martin Metz was an investigator of this phase II study and has acted as a speaker/ consultant for Novartis.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of EADV Virtual Congress 2020
Share this Video
Related Videos In Dermatological Conditions
Esther van Zuuren, EADV 2021: Topical Therapies in Rosacea
It was a pleasure to speak with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) about current and emerging topical therapies in rosacea. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you give us an overview of the current […]
Esther van Zuuren, EADV 2021: Rosacea Classification
It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]
Dedee Murrell, AAD VMX 2021: BELIEVE Phase 2 Study of Rilzabrutinib in Pemphigus
It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus. Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!